Reference : Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/84988
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
English
Scherpereel, a [ > > ]
Berghmans, t [ > > ]
Lafitte, j.j [ > > ]
Colinet, b [ > > ]
Richez, m [ > > ]
Bonduelle, y [ > > ]
Meert, a.p [ > > ]
Dhalluin, x [ > > ]
Leclercq, n [ > > ]
Paesmans, m [ > > ]
Willems, Luc mailto [Université de Liège - ULg > Chimie et bio-industries > Centre de Bio. Fond. - Section de Biologie cell. et moléc. >]
Sculier, j.p [ > > ]
Jan-2011
European Respiratory Journal
European Respiratory Society
37
129-135
Yes (verified by ORBi)
International
0903-1936
1399-3003
Lausanne
Switzerland
[en] valproic acid ; doxorubicin ; mesothelioma ; histone deacetylase inhibitors ; Chemotherapy
[en] No treatment is recommended for patients with malignant mesothelioma (MM) failing after first-line cisplatin-based chemotherapy. In vitro data suggested that valproic acid, a histone deacetylase inhibitor (HDACi), had a proapoptotic effect and synergised with doxorubicin to induce apoptosis in MM cells. Our primary end-point was to determine response rate of combined valproic acid and doxorubicin in patients with unresectable MM failing after platinum based chemotherapy.
Treatment consisted of doxorubicin (60 mg?m-2) plus valproic acid. An interim analysis for
response rate was planned after the first 16 registered patients. All the cases were centrally
reviewed.
From July 2006 to March 2009, 45 eligible patients with pleural MM were registered. The majority of the patients were male (73%), had a performance status (PS) o80 (76%) and an
epithelioid subtype (80%). There were seven partial responses (response rate 16%; 95% CI 3–
25%), all in patients with PS 80–100. The best disease control rate was 36% (95% CI 22–51%). Two toxic deaths were observed (febrile neutropenia and cerebral thrombotic event), both in patients with poor PS (60–70). Valproic acid, an HDACi, plus doxorubicin appeared an effective chemotherapy regimen in good PS (80–100) patients with refractory or recurrent MM, for which no standard therapy was available.
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/84988
10.1183/09031936.00037310

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
2011_ERJ_Scherpereel.pdfPublisher postprint315.72 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.